KKPCF

Kaken Pharmaceutical Co. Ltd

KKPCF, USA

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

https://www.kaken.co.jp

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

Semiannual

Rate:

0.6414

Next Payout:

Jun 1, 2026

Yield:

9.1234 %

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

262.78

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.01

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.00 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.00 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Kaken Pharmaceutical Co. Ltd

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0.1291

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(2.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7.5)
Net Net
Strong Net-Net(8)
Quality
Moderate Quality(4.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.